Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
NEW HAVEN, Conn.–(BUSINESS WIRE)– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Kanuma ® (sebelipase alfa)...